SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Xeris Biopharma Holdings, Inc. (XERS) trades at a trailing P/E of 1,731.5, forward P/E of 50.6. Trailing earnings yield is 0.06%, forward earnings yield 1.98%. PEG 0.01 (Peter Lynch undervalued ≤1.0). Graham Number is $0.08.
Criteria proven by this page:
- VALUE (34/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 1,731.5); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY 0.06%).
- Forward P/E 50.6 (down from trailing 1,731.5) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 0.06% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 1.98% as earnings recover.
- Analyst consensus target $13.50 (+122.4% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
34/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — XERS
Valuation Multiples
P/E (TTM)1,731.5
Forward P/E50.6
PEG Ratio0.01
Forward PEG0.01
P/B Ratio70.08
P/S Ratio3.42
EV/EBITDA26.4
Per Share Data
EPS (TTM)$0.00
Forward EPS (Est.)$0.12
Book Value / Share$0.08
Revenue / Share$1.76
FCF / Share$0.23
Yields & Fair Value
Earnings Yield0.06%
Forward Earnings Yield1.98%
Dividend Yield0.00%
Graham Number$0.08
SharesGrow IV$2.23 (-63.3%)
Analyst Target$13.50 (+122.4%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-2.8 |
0.00 |
-1.17 |
34.65 |
- |
| 2017 |
-1.5 |
-0.02 |
-0.71 |
26.36 |
- |
| 2018 |
-3.4 |
0.06 |
2.72 |
83.08 |
- |
| 2019 |
-1.5 |
0.05 |
12.75 |
67.63 |
- |
| 2020 |
-2.3 |
0.06 |
6.21 |
10.27 |
- |
| 2021 |
-1.9 |
0.07 |
2.43 |
4.67 |
- |
| 2022 |
-1.9 |
0.03 |
3.99 |
1.64 |
- |
| 2023 |
-5.2 |
0.15 |
-47.71 |
1.97 |
- |
| 2024 |
-9.1 |
0.51 |
-16.80 |
2.45 |
- |
| 2025 |
2,273.2 |
-22.52 |
92.00 |
4.32 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-7.17 |
$1.08M |
$-13.21M |
-1228.7% |
| 2017 |
$-13.09 |
$1.56M |
$-26.55M |
-1706.6% |
| 2018 |
$-4.99 |
$2.47M |
$-60.08M |
-2437.3% |
| 2019 |
$-3.49 |
$20.16M |
$-91.14M |
-452.2% |
| 2020 |
$-2.88 |
$49.59M |
$-122.73M |
-247.5% |
| 2021 |
$-1.55 |
$49.59M |
$-122.73M |
-247.5% |
| 2022 |
$-0.70 |
$110.25M |
$-94.66M |
-85.9% |
| 2023 |
$-0.45 |
$163.91M |
$-62.26M |
-38% |
| 2024 |
$-0.37 |
$203.07M |
$-54.84M |
-27% |
| 2025 |
$0.00 |
$291.85M |
$554K |
0.2% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$0.12 |
$0.06 – $0.20 |
$384.03M |
$381.18M – $388.56M |
4 |
| 2027 |
$0.35 |
$0.17 – $0.45 |
$472.23M |
$459.37M – $488.06M |
4 |
| 2028 |
$0.59 |
$0.38 – $0.82 |
$540.02M |
$540.02M – $540.02M |
5 |
| 2029 |
$0.89 |
$0.87 – $0.93 |
$607.63M |
$594.87M – $627.78M |
1 |
| 2030 |
$1.09 |
$1.06 – $1.14 |
$701.45M |
$686.72M – $724.71M |
1 |
